Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
Pfister C, Harter V, Allory Y, Radvanyi F, Culine S; VESPER Trial Investigators. Pfister C, et al. Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar. Contemp Clin Trials Commun. 2020. PMID: 32083220 Free PMC article.
Is multidetector CT-scan able to detect T3a renal tumor before surgery?
Renard AS, Nedelcu C, Paisant A, Saulnier P, Le Bigot J, Azzouzi AR, Bigot P, Aubé C. Renard AS, et al. Among authors: azzouzi ar. Scand J Urol. 2019 Oct;53(5):350-355. doi: 10.1080/21681805.2019.1675756. Epub 2019 Oct 12. Scand J Urol. 2019. PMID: 31607203
Double J stenting evaluation after ureteroscopy for urolithiasis.
Segalen T, Lebdai S, Panayotopoulos P, Culty T, Brassart E, Riou J, Azzouzi AR, Bigot P. Segalen T, et al. Among authors: azzouzi ar. Prog Urol. 2019 Oct;29(12):589-595. doi: 10.1016/j.purol.2019.08.266. Epub 2019 Sep 7. Prog Urol. 2019. PMID: 31506249
A Multicenter, Randomized, Placebo-Controlled Study Evaluating the Efficacy of a Combination of Propolis and Cranberry (Vaccinium macrocarpon) (DUAB®) in Preventing Low Urinary Tract Infection Recurrence in Women Complaining of Recurrent Cystitis.
Bruyère F, Azzouzi AR, Lavigne JP, Droupy S, Coloby P, Game X, Karsenty G, Issartel B, Ruffion A, Misrai V, Sotto A, Allaert FA. Bruyère F, et al. Among authors: azzouzi ar. Urol Int. 2019;103(1):41-48. doi: 10.1159/000496695. Epub 2019 May 22. Urol Int. 2019. PMID: 31117097 Clinical Trial.
Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer.
Lebdai S, Gigoux M, Alvim R, Somma A, Nagar K, Azzouzi AR, Cussenot O, Merghoub T, Wolchok JD, Scherz A, Kim K, Coleman J. Lebdai S, et al. Among authors: azzouzi ar. Oncoimmunology. 2019 Mar 28;8(6):e1581528. doi: 10.1080/2162402X.2019.1581528. eCollection 2019. Oncoimmunology. 2019. PMID: 31069149 Free PMC article.
146 results